| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
4-Deoxypyridoxine hydrochloride targets vitamin B6 metabolism as an antimetabolite. It inhibits the transport of pyridoxine and inhibits S1P lyase (SPL) activity, which degrades intracellular sphingosine-1-phosphate (S1P). By inhibiting SPL, it minimizes chemically induced apoptosis of insulinoma cell lines.
|
|---|---|
| ln Vitro |
The in vitro activity of 4-Deoxypyridoxine hydrochloride is its function as a vitamin B6 antimetabolite. The compound inhibits the transport of pyridoxine and inhibits S1P lyase (SPL) activity. By inhibiting SPL, it minimizes the chemically induced apoptosis of insulinoma cell lines. The compound can induce a deficient status that alters the function and ultrastructure of EC similar to vascular disease.
|
| ln Vivo |
In vivo, 4-Deoxypyridoxine can induce a deficient status that alters the function and ultrastructure of EC similar to vascular disease. No other significant in vivo activity has been reported as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for 4-Deoxypyridoxine hydrochloride involve measuring its inhibition of S1P lyase (SPL) activity. The compound is incubated with SPL enzyme preparations in appropriate buffer conditions, and the inhibition of S1P degradation is measured.
|
| Cell Assay |
For in vitro cellular experiments, 4-Deoxypyridoxine hydrochloride can be used to study the effects of vitamin B6 deficiency and SPL inhibition on cellular function. Insulinoma cell lines are treated with the compound to assess its effects on apoptosis.
|
| Animal Protocol |
In vivo animal experiments with 4-Deoxypyridoxine hydrochloride may be performed to study the effects of vitamin B6 deficiency on vascular function.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Deoxypyridoxine hydrochloride have not been extensively characterized, as it is a research-use biochemical reagent rather than a drug candidate. The compound has a molecular weight of 189.64 g/mol and a melting point of 263-265°C.
|
| Toxicity/Toxicokinetics |
The compound is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| Additional Infomation |
4-Deoxypyridoxine hydrochloride is a structural analog of pyridoxine (vitamin B6) that functions as a vitamin B6 antimetabolite. It inhibits S1P lyase activity and minimizes apoptosis of insulinoma cell lines. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C8H12CLNO2
|
|---|---|
| Molecular Weight |
189.64
|
| Exact Mass |
189.055
|
| CAS # |
148-51-6
|
| Related CAS # |
61-67-6 (Parent)
|
| PubChem CID |
67417
|
| Appearance |
White to off-white solid powder
|
| Density |
1.201g/cm3
|
| Boiling Point |
414.1ºC at 760 mmHg
|
| Melting Point |
274°C(dec.)(lit.)
|
| Flash Point |
204.2ºC
|
| Vapour Pressure |
1.34E-07mmHg at 25°C
|
| LogP |
1.698
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
129
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O([H])C1C(C([H])([H])[H])=NC([H])=C(C([H])([H])O[H])C=1C([H])([H])[H]
|
| InChi Key |
QZKKOQQIVLXUEI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H11NO2.ClH/c1-5-7(4-10)3-9-6(2)8(5)11;/h3,10-11H,4H2,1-2H3;1H
|
| Chemical Name |
5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2731 mL | 26.3657 mL | 52.7315 mL | |
| 5 mM | 1.0546 mL | 5.2731 mL | 10.5463 mL | |
| 10 mM | 0.5273 mL | 2.6366 mL | 5.2731 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
